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Cardiotrophin (CT-1) is a naturally occurring protein
member of the interleukin (IL)-6 cytokine family and
signals through the gp130/leukemia inhibitory factor receptor (LIFR) heterodimer. The formation of gp130/
LIFR complex triggers the auto/trans-phosphorylation
of associated Janus kinases, leading to the activation of
Janus kinase/STAT and MAPK (ERK1 and -2) signaling
pathways. Since adipocytes express both gp130 and
LIFR proteins and are responsive to other IL-6 family
cytokines, we examined the effects of CT-1 on 3T3-L1
adipocytes. Our studies have shown that CT-1 administration results in a dose- and time-dependent activation
and nuclear translocation of STAT1, -3, -5A, and -5B as
well as ERK1 and -2. We also confirmed the ability of
CT-1 to induce signaling in fat cells in vivo. Our studies
revealed that neither CT-1 nor ciliary neurotrophic factor treatment affected adipocyte differentiation. However, acute CT-1 treatment caused an increase in
SOCS-3 mRNA in adipocytes and a transient decrease in
peroxisome proliferator-activated receptor ␥ (PPAR␥)
mRNA that was regulated by the binding of STAT1 to the
PPAR␥2 promoter. The effects of CT-1 on SOCS-3 and
PPAR␥ mRNA were independent of MAPK activation.
Chronic administration of CT-1 to 3T3-L1 adipocytes
resulted in a decrease of both fatty acid synthase and
insulin receptor substrate-1 protein expression yet did
not effect the expression of a variety of other adipocyte
proteins. Moreover, chronic CT-1 treatment resulted in
the development of insulin resistance as judged by a
decrease in insulin-stimulated glucose uptake. In summary, CT-1 is a potent regulator of signaling in adipocytes in vitro and in vivo, and our current efforts are
focused on determining the role of this cardioprotective
cytokine on adipocyte physiology.

Cardiotrophin (CT-1),1 first identified in a screen of a cDNA
library derived from the mouse embryoid bodies, has been
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shown to support in vitro cardiomyocyte survival and hypertrophy. CT-1 is a naturally occurring protein, 200 amino acids
long, with a molecular mass of ⬃21.5 kDa (1). CT-1 mRNA
expression has been detected at high levels in the heart, skeletal muscle, prostate, ovaries, and liver, as well as fetal heart,
lung, and kidney. Lower amounts have also been detected in
the thymus, small intestine, lung, kidney, pancreas, testes, and
brain, whereas no expression was observed in the spleen (2).
Sequence analyses and structural considerations have shown
that CT-1 is a member of the IL-6 cytokine family (2). The
members of this family do not share a great deal of primary
amino acid sequence homology (14 –24%) (3), but they do share
common structural features (4) and utilize gp130 signal transducer protein in their receptor complexes (5). Both functional
and receptor binding studies in cultured cardiomyocytes have
shown that CT-1 signals through the gp130/LIFR heterodimer
without the further requirement for the ␣-subunit (6 – 8). However, CT-1 signaling in neuronal cells may require an additional 80-kDa ␣-subunit (45 kDa after N-linked deglycosylation) present in the receptor complexes in addition to gp130 and
LIFR (6, 9). These studies have also shown that CT-1 binds the
LIFR with affinity equivalent to that of LIF but fails to bind
gp130 alone. However, the addition of gp130 enhances its binding to LIFR. From these observations, it has been deduced that
CT-1 initially binds LIFR with a low affinity, followed by the
recruitment of gp130 into a high affinity binding complex (7).
The formation of gp130/LIFR complex triggers the activation
and auto/trans-phosphorylation of receptor-associated JAK
kinases.
The activation of JAK family kinases leads to the phosphorylation of the receptor subunits, which can then recruit STAT1
and STAT3, leading to their phosphorylation, nuclear translocation, and the ability to regulate gene expression. Phosphorylated receptor subunits can also recruit the Src homology
domain 2 adapter Shc, leading to a complex formation with
Grb2 and SOS (10). Grb2-SOS complexes can then activate
p21ras, leading to the subsequent, cell type-specific, activation
of raf-1, MEK, and ERK1/2 MAPKs (11, 12).
As previously noted CT-1 was first identified as a factor
promoting cardiac myocyte hypertrophy in vitro with activity
at concentrations (0.1 nM) much lower than other IL-6 family
cytokines. Similarly, an in vivo chronic administration of CT-1
to rodents resulted in dose-dependent increases in both heart
weight and ventricular weight, whereas the total body weight
was unaffected (13). These results mimicked those of chronic in
vivo stimulation of gp130 receptor (14). It has been suggested
that this function of CT-1 is governed through its activation of
the JAK/STAT pathway (15).
CT-1 has also been shown to reduce the expression of tumor
necrosis factor-␣ in lipopolysaccharide-treated animals (16).
Elevated tumor necrosis factor-␣ levels have been correlated
with myocardial infarction and chronic heart failure (17) as
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well as the development of insulin resistance in type 2 diabetes
(18). Like other IL-6 cytokine family members, CT-1 can induce
liver acute phase response (19). In vivo administration of CT-1
has also resulted in hypertrophy of the liver, kidneys, and
spleen, atrophy of the thymus, and increasing platelet and red
blood cell counts (13). Also, CT-1 supports the long term survival of spinal motor neurons and ciliary ganglion neurons, and
the effects of CT-1 on ciliary ganglions mimic those of CNTF
(7).
Previous work from our laboratory has shown that CNTF
activates JAK/STAT and MAPK (ERK1 and -2) pathways in
adipocytes and has several effects on adipocyte physiology (20).
Because of its ability to potently activate the JAK/STAT pathway through the gp130/LIFR dimer, we predicted that CT-1
could affect adipocyte physiology and gene expression. Indeed,
we have observed that CT-1 activates the JAK/STAT pathway
and ERK signaling pathway in fat cells in vitro and in vivo.
Although this gp130 cytokine does not attenuate 3T3-L1 adipocyte differentiation, we have observed that CT-1 decreased
fatty acid synthase and IRS-1 protein in mature adipocytes and
results in a decrease of insulin-stimulated glucose uptake. In
addition, we have shown that CT-1 induces SOCS-3 mRNA and
acutely represses PPAR␥ expression. The CT-1-induced repression of PPAR␥ correlates with binding of STAT 1 to the
PPAR␥2 promoter, and mutation of this site indicates that it
contributes to the expression of PPAR␥2 under basal conditions. We have also observed that these effects of CT-1 are
independent of ERK1 and -2. To our knowledge, this is the first
study to demonstrate the effects of CT-1 on fat cells. Recently,
it has been shown that the circulating levels of CT-1 are increased in the serum of patients with ischemic heart disease
and valvular heart disease (21). Since the onset of cardiovascular disease can be associated with obesity/type 2 diabetes (22,
23), the actions of CT-1 in fat may prove to be a relevant link
between these two deadly diseases.
EXPERIMENTAL PROCEDURES

Materials—Dulbecco’s modified Eagle’s medium was purchased from
Invitrogen. Bovine and fetal bovine sera were purchased from Sigma
and Invitrogen, respectively. Rat recombinant CNTF and human recombinant CT-1 were purchased from Calbiochem. Mouse recombinant
LIF was purchased from Chemicon International. Insulin and human
recombinant growth hormone were purchased from Sigma. U0126 was
purchased from Promega. DNase I and Trizol were purchased from
Invitrogen. All STAT antibodies were monoclonal IgGs purchased from
Transduction Laboratories or polyclonal IgGs purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). The highly phosphospecific
polyclonal antibodies for STAT1 (Tyr701), STAT3 (Tyr705), and STAT5
(Tyr694) were IgGs purchased from BD Transduction Laboratories and
Upstate Biotechnology, Inc. (Lake Placid, NY). Sterol regulatory element-binding protein-1 antibody was a rabbit polyclonal IgG, whereas
PPAR␥ antibody was a mouse monoclonal IgG, both purchased from
Santa Cruz Biotechnology. ERK1/ERK2 antibody was a rabbit polyclonal IgG purchased from Santa Cruz Biotechnology. Active ERK
antibody was a rabbit polyclonal IgG purchased from Cell Signaling
Technology. Akt and FAS antibodies were rabbit polyclonal IgGs purchased from BD Transduction Laboratories. IRS-1 antibody was a polyclonal IgG purchased from Upstate Biotechnology. Horseradish peroxidase-conjugated streptavidin used for detection of ACC was purchased
from Pierce. Horseradish peroxidase-conjugated secondary antibodies
were purchased from Jackson Immunoresearch. An enhanced chemiluminescence kit was purchased from Pierce. Nitrocellulose and Zeta
Probe-GT membranes were purchased from Bio-Rad.
Cell Culture—Murine 3T3-L1 preadipocytes were plated and grown
to 2 days postconfluence in Dulbecco’s modified Eagle’s medium with
10% bovine serum. Medium was changed every 48 h. Cells were induced
to differentiate by changing the medium to Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum, 0.5 mM 3-isobutyl-1-methylxanthine, 1 M dexamethasone, and 1.7 M insulin. After 48 h, this
medium was replaced with Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, and cells were maintained in
this medium until utilized for experimentation.
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Preparation of Whole Cell Extracts—Monolayers of 3T3-L1 preadipocytes or adipocytes were rinsed with phosphate-buffered saline and
then harvested in a nondenaturing buffer containing 150 mM NaCl, 10
mM Tris, pH 7.4, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5%
Igepal CA-630 (Nonidet P-40), 1 M phenylmethylsulfonyl fluoride, 1
M pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10 M leupeptin, and 2 mM sodium vanadate. Samples were extracted for 30 min
on ice and centrifuged at 15,000 rpm at 4 °C for 15 min. Supernatants
containing whole cell extracts were analyzed for protein content using
a BCA kit (Pierce) according to the manufacturer’s instructions.
Preparation of Nuclear and Cytosolic Extracts—Cell monolayers
were rinsed with phosphate-buffered saline and then harvested in a
nuclear homogenization buffer containing 20 mM Tris (pH 7.4), 10 mM
NaCl, and 3 mM MgCl2. Igepal CA-630 (Nonidet P-40) was added to a
final concentration of 0.15%, and cells were homogenized with 16
strokes in a Dounce homogenizer. The homogenates were centrifuged at
1500 rpm for 5 min. Supernatants were saved as cytosolic extract, and
the nuclear pellets were resuspended in half the volume of nuclear
homogenization buffer and were centrifuged as before. The pellet of
intact nuclei was resuspended again in half of the original volume of
nuclear homogenization buffer and centrifuged again. A small portion
of the nuclei was used for trypan blue staining to examine the integrity
of the nuclei. The majority of the pellet (intact nuclei) was resuspended
in an extraction buffer containing 20 mM HEPES (pH 7.9), 420 mM
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, and 25% glycerol. Nuclei were
extracted for 30 min on ice and then placed at room temperature for 10
min. Two hundred units of DNase I was added to each sample, and
tubes were inverted and incubated an additional 10 min at room temperature. Finally, the sample was subjected to centrifugation at 15,000
rpm at 4 °C for 30 min. Supernatants containing nuclear extracts were
analyzed for protein content, using a BCA protein assay kit (Pierce).
Gel Electrophoresis and Western Blot Analysis—Proteins were separated in 5, 7.5, 10, or 12% polyacrylamide (acrylamide from National
Diagnostics) gels containing SDS according to Laemmli (24) and transferred to nitrocellulose membrane in 25 mM Tris, 192 mM glycine, and
20% methanol. Following transfer, the membrane was blocked in 4%
fat-free milk for 1 h at room temperature. Results were visualized with
horseradish peroxidase-conjugated secondary antibodies and enhanced
chemiluminescence.
RNA Analysis—Total RNA was isolated from cell monolayers with
Trizol according to the manufacturer’s instructions with minor modifications. For Northern blot analysis, 20 g of total RNA was denatured
in formamide and electrophoresed through a formaldehyde-agarose gel.
The RNA was transferred to Zeta Probe-GT, cross-linked, hybridized,
and washed as previously described (18). Probes were labeled by random priming using the Klenow fragment and [␣-32P]dATP.
Rodent Adipose Tissue Isolation—Animals were euthanized by cervical dislocation, and tissues were immediately removed and frozen in
liquid nitrogen. Frozen tissues were homogenized in a buffer containing
150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EGTA, 1 mM EDTA, 1% Triton
X-100, 0.5% Igepal CA-630 (Nonidet P-40), 1 M phenylmethylsulfonyl
fluoride, 1 M pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10
M leupeptin, and 2 mM sodium vanadate. Homogenates were centrifuged for 10 min at 5,000 rpm to remove any debris and insoluble
material and then analyzed for protein content. All C57Bl/6J mice were
obtained from a colony at the Pennington Biomedical Research Center.
All animal studies were carried out with protocols that were reviewed
and approved by institutional animal care and use committees.
Electromobility Shift Assays—Double-stranded oligonucleotides
were annealed by heating single-stranded 5⬘ and 3⬘ oligonucleotides in
a boiling water bath and gradually cooling to room temperature. The 4
g of double-stranded oligonucleotides were 5⬘-end-labeled with 20 Ci
of [32P]dCTP (400 – 800 Ci/mmol) and with 1 ml each of 5 mM dATP,
dTTP, and dGTP with Klenow fragment. The end-labeling reaction was
incubated for 15 min at 30 °C and was stopped by adding 1 l of 0.5 M
EDTA. End-labeled oligonucleotides were purified using a Princeton
CENTRISEP column, according to the manufacturer’s instructions
(Princeton Separations, Inc.). Specific activity of the oligonucleotides
was determined by scintillation counting. Nuclear extracts were incubated with the end-labeled oligonucleotides (50,000 cpm/l) for 30 min
on ice. The samples were loaded into a prerun (1 h, 100 V at 4 °C) 6%
acrylamide/bisacrylamide TBE gel containing 90 mM Tris, 90 mM boric
acid, and 2 mM EDTA, pH 8.0. For supershift analysis, nuclear extracts
were preincubated with antibody for 1 h at room temperature. For cold
competition, the nuclear extracts were incubated with unlabeled oligonucleotide for 15 min on ice prior to incubation with the labeled probe.
The gels were run at 20 mA for ⬃2 h, dried at 80 °C for 1 h under a
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FIG. 1. The effects of acute CT-1 treatment on 3T3-L1 preadipocytes and adipocytes. Whole cell extracts were prepared from
confluent undifferentiated preadipocytes and from fully differentiated
3T3-L1 adipocytes following a treatment with 0.2 nM CT-1 for the times
indicated. One hundred twenty-five g of each extract was separated by
SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot
analysis.
vacuum, and then exposed to Eastman Kodak Co. BioMax MS film with
a Kodak BioMax high energy intensifying screen.
Constructs—The PPAR␥2 promoter (⫺609 to ⫹52) luciferase construct was a generous gift of Dr. Jeffrey Gimble, (Pennington Biomedical Research Center). The PPAR␥2 promoter (⫺609 to ⫹52) luciferase
construct was mutated at positions ⫺217 and ⫺212 within the STAT
recognition element using the QuikChange site-directed mutagenesis
kit according to the manufacturer’s instructions (Stratagene). The following oligonucleotide and corresponding antisense oligonucleotide was
used to mutate the STAT recognition element (GAC AAT GTA GCA
ACG TTC TCC TCG TAA TGT ACC AAG TC). The mutated bases were
altered from T to C and are underlined. The resulting reporter plasmid
was termed PPAR␥2 m217/212 (⫺609 to ⫹52). The change in sequence
was confirmed by sequencing using a Big Dye Terminator Extension
Reaction (ABI Prism). The minimum promoter thymidine kinase Renilla promoter was obtained from Promega.
Transfections—3T3-L1 preadipocytes were grown to 60% confluence
and were transiently transfected with the PPAR␥2 promoter (⫺609 to
⫹52)/luciferase construct or the PPAR␥2 m217/212 (⫺609 to ⫹52)/
luciferase construct and with the thymidine kinase/Renilla vector to
control for transfection efficiency, using Polyfect transfection reagent
according to the manufacturer’s instructions (Qiagen). After 48 h of
incubation with the Polyfect-DNA solution, cells were treated and then
harvested for analysis for firefly luciferase and Renilla luciferase activity using the Dual Luciferase Reporter Assay System (Promega). Relative light units were determined by dividing firefly luciferase activity by
Renilla luciferase activity. Results are given ⫾ S.D.
Determination of 3H-Labeled 2-Deoxyglucose Uptake—The assay of
3
H-labeled 2-deoxyglucose uptake was performed as previously described (18). Prior to the assay, fully differentiated 3T3-L1 adipocytes
were serum-deprived for 4 h. Uptake measurements were performed in
triplicate under conditions where hexose uptake was linear. The results
were corrected for nonspecific uptake, and absorption was determined
by 3H-labeled 2-deoxyglcuose uptake in the presence of 5 M cytochalasin B. Nonspecific uptake and absorption was always less than 10% of
the total uptake.
RESULTS

In order to examine the sensitivity of 3T3-L1 cells to CT-1
administration, confluent 3T3-L1 preadipocytes and fully differentiated 3T3-L1 adipocytes were treated with CT-1 (0.20 nM)
for the times indicated in Fig. 1. Western blot analysis of cell
extracts revealed that both undifferentiated and differentiated
3T3-L1 cells responded to CT-1 treatment in a time-dependent
manner. Exposure to CT-1 resulted in a time-dependent activation and tyrosine phosphorylation of STAT1 and -3 as well as
activation of MAPK (ERK1 and -2). The magnitudes of the
responses were undistinguishable in undifferentiated and differentiated 3T3-L1 cells. However, the tyrosine phosphorylation of STAT3 was sustained for a longer period of time in
preadipocytes. The total levels of MAPK are shown as a control
for even loading.
The subcellular distribution of STAT proteins following CT-1
treatment was assessed by treating fully differentiated 3T3-L1
adipocytes with CT-1 (0.20 nM) for various periods of time,

FIG. 2. The effects of acute CT-1 treatment on the activation
and nuclear translocation of STAT proteins in 3T3-L1 adipocytes. Cytosolic and nuclear extracts were prepared from fully differentiated 3T3-L1 adipocytes following a treatment with 0.2 nM CT-1 for
the times indicated. One hundred g of each extract was separated by
SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot
analysis.

followed by isolation of cytosolic and nuclear extracts. Western
blot analysis of these extracts, shown in Fig. 2, clearly demonstrated that CT-1 treatment results in the nuclear translocation of STAT1, -3, -5A, and -5B as well as the activation of
MAPK. For each STAT protein examined, nuclear translocation occurred within 15 min and returned to basal level within
2 h following the cytokine treatment. This pattern is consistent
with STAT activation by CNTF and other gp130 cytokines in
3T3-L1 adipocytes (20).
To further examine the ability of CT-1 to activate STATs in
3T3-L1 adipocytes in comparison with other gp130 cytokines,
we exposed fully differentiated adipocytes to various doses of
CT-1, CNTF, and LIF for 15 min. Western blot analysis of
whole cell extracts, shown in Fig. 3, indicated that the activation of STAT1, -3, and -5 and MAPK (ERK1 and -2) by CT-1 is
dose-dependent. Moreover, the STAT3 activation was achieved
at much lower doses of CT-1 than those required for activation
of STAT1 and STAT5. However, as previously shown, CNTF
does not activate STAT3 in a dose-dependent manner (20).
CNTF treatment also did not result in either STAT1 or STAT5
activation. Treatment with 2.0 nM CNTF resulted in substantially less STAT 3 and MAPK activation when compared with
2.0 nM CT-1. LIF treatment also resulted in a dose-dependent
activation of STAT1, -3, and -5 and MAPK in a manner and
dose comparable with that of CT-1. The total levels of MAPK
are shown as a control for even loading.
To determine if CT-1 could affect signaling pathways in
adipose tissue in vivo, the effects of this cytokine were examined in 7-week-old C57B1/6J mice given an intraperitoneal
injection of CT-1 (0.5 g/animal) or vehicle (saline) control and
sacrificed after 15 min. Western blot analysis of whole tissue
extracts isolated from the epididymal fat pads of the animals,
shown in Fig. 4, demonstrated that the four mice injected with
CT-1 had a significant increase in levels of active MAPK and
tyrosine-phosphorylated STAT1 and -3. However, there was no
detectable STAT activation in the four saline-injected mice,
although some active MAPK was observed. Also, the activation
of STAT5 proteins by CT-1 was not observed under these conditions. The total levels of MAPK are shown as a control for
even loading, whereas an extract from 3T3-L1 adipocytes
treated with growth hormone was used as a positive control for
STAT5 activation (25).
The differentiation of 3T3-L1 preadipocytes into mature adipocytes is governed by a variety of cell signals. Hence, we
examined the ability of CT-1 to modulate adipogenesis of
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FIG. 3. Dose-dependent effects of
CT-1 on 3T3-L1 adipocytes. Whole cell
extracts were prepared from fully differentiated 3T3-L1 adipocytes following a
15-min treatment with CT-1, CNTF, or
LIF, with the doses indicated in the figure. One hundred fifty g of each extract
was separated by SDS-PAGE, transferred
to nitrocellulose, and subjected to Western blot analysis.

FIG. 4. In vivo effect of acute CT-1 administration in rodents.
Seven-week-old male C57B1/6J mice were given an intraperitoneal
injection of 0.1 nM CT-1 (0.5 g/animal) or vehicle (saline) control.
Fifteen min after the injection, the mice were sacrificed, and epididymal
fat pads were immediately removed and frozen in liquid nitrogen. One
hundred fifty g of each tissue extract was separated by SDS-PAGE,
transferred to nitrocellulose, and subjected to Western blot analysis.

3T3-L1 cells. Our results clearly demonstrated that neither
CT-1 nor CNTF treatment had any profound effects on adipocyte differentiation, as evident by the unaltered expression
levels of various adipocyte proteins including PPAR␥, IRS-1,
STAT5A, and ACC (data not shown). Since CT-1 did not affect
the adipogenesis of 3T3-L1 cells, we examined the effects of this
cytokine on the expression of genes in fully differentiated
3T3-L1 adipocytes. Since this cytokine is a potent STAT activator, both in vitro and in vivo (Figs. 2 and 4), we hypothesized
that activated STATs would modulate transcription in fat cells.
Serum-deprived, fully differentiated 3T3-L1 adipocytes were
treated with CT-1 (0.20 nM) or CNTF (0.45 nM) for various

FIG. 5. The effects of acute CT-1 and CNTF administration on
the expression of adipocyte proteins. Total RNA (A and C) or whole
cell extracts (B) were isolated from fully differentiated 3T3-L1 adipocytes following a treatment with CT-1 (0.2 nM), CNTF (0.45 nM), or
U0126 (5.0 M) for the times shown. Twenty g of each total RNA was
electrophoresed, transferred to nylon, and subjected to Northern blot
analysis. One hundred g of each whole cell extract was separated by
SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot
analysis.
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FIG. 6. CT-1 induces STAT1 binding
to the ⴚ221 to ⴚ207 element of the
PPAR␥2 promoter in vitro. A, nuclear
extracts were prepared from 3T3-L1 adipocytes that were untreated or treated
with the indicated dose of CT-1 for 15
min. The extracts were incubated with a
32
P-labeled oligonucleotide of the ⫺221 to
⫺207 region of the PPAR␥2 promoter for
analysis by an electromobility shift assay.
B, nuclear extracts were prepared from
3T3-L1 adipocytes that were untreated or
treated with 0.3 nM CT-1 for 15 min. The
extracts were preincubated with antibodies for STAT1, -3, or -5A for supershift
analysis. The extracts were then incubated with the 32P-labeled ⫺221 to ⫺207
oligonucleotide. C, prior to incubation
with the 32P-labeled ⫺221 to ⫺207 oligonucleotide, nuclear extracts from CT-1treated 3T3-L1 adipocytes were incubated
with unlabeled oligonucleotides of the
⫺221 to ⫺207 sequence from the PPAR␥2
promoter, a mutated sequence of the
⫺221 to ⫺207 element, the ⫺431 to ⫺408
sequence of the PPAR␥2 promoter, or the
⫺107 to ⫺91 sequence from the PPAR␥2
promoter. D, 3T3-L1 adipocytes were pretreated with U0126 for 45 min and were
then treated for 15 min with 0.3 nM CT-1.
Nuclear extracts from these cells were
then incubated with the 32P-labeled ⫺221
to ⫺207 oligonucleotide for electromobility shift analysis. E, 3T3-L1 preadipocytes were transiently transfected with
either the PPAR␥2 promoter (⫺609 to
⫹52)/luciferase reporter wild-type (WT)
construct or with the PPAR␥2 m217/212
(⫺609 to ⫹52)/luciferase reporter mutant
(Mut) construct. The cells were also transfected with the thymidine kinase/Renilla
construct to normalize for transfection
variability. After 48 h, the cells were untreated or treated with 0.4 nM CT-1 for 6 h
and then were harvested for analysis.
Relative light units (RLU) was calculated
by dividing the luciferase reporter activity by the Renilla luciferase activity. Results are shown as mean ⫾ S.D.

times, indicated in Fig. 5. Total RNA and whole cell extracts
were collected following the treatment. As shown in Fig. 5A,
both CT-1 and CNTF administration resulted in a rapid induction of SOCS-3 mRNA levels. However, this up-regulation was
very transient following CNTF treatment, whereas CT-1 treatment, at a dose lower than that of CNTF, resulted in a more
sustained induction of SOCS-3 mRNA. Both cytokines also
resulted in a transient down-regulation of PPAR␥ mRNA,
which was more evident following a 2-h CT-1 treatment. The
levels of aP2 mRNA were unchanged. The efficacy of the cytokines in this experiment was demonstrated by their ability to
induce STAT3 phosphorylation (Fig. 5B). Since CT-1 is a potent
activator of the MAPK pathway, we set out to determine
whether the repression of PPAR␥ mRNA or induction of
SOCS-3 mRNA induced by CT-1 was mediated through this
pathway by pretreating 3T3-L1 adipocytes with U0126, a MEK
inhibitor. The Northern blot analysis in Fig. 5C clearly demonstrates that both SOCS-3 mRNA up-regulation and PPAR␥
mRNA down-regulation are not dependent on the activity of
ERK1 and -2, because the addition of U0126 failed to prevent
modulation of mRNA levels by CT-1. The efficacy of U0126 was

confirmed by the loss of MAPK (ERK1 and -2) activation following an acute CT-1 treatment (data not shown).
Previous work from our laboratory has shown that downregulation of PPAR␥ by interferon-␥ can occur at the level of
transcription and may be mediated by STAT1 binding to the
⫺221 to ⫺207 element of the PPAR␥2 promoter (26). Therefore,
we examined the ability of CT-1-activated STAT1 proteins to
bind the ⫺221 to ⫺207 element of the PPAR␥2 promoter. To
analyze the binding of protein complexes to the ⫺221 to ⫺207
oligonucleotide, electromobility shift assays were performed
with nuclear extracts from 3T3-L1 adipocytes acutely treated
with CT-1 for 15 min. As shown in Fig. 6A, two protein complexes that shifted the ⫺221 to ⫺207 oligonucleotide were
detected, but only the slower migrating band was induced with
CT-1 treatment in a dose-dependent manner (lane 2). In order
to determine whether the CT-1-induced protein complex contained STAT proteins, a supershift analysis was performed,
using antibodies for STAT1, -3, and -5A. The STAT1 antibody
fully supershifted the CT-1-induced protein complex (lane 3);
however, the STAT3 and -5A antibodies did not affect the
mobility of the protein complex, as shown in Fig. 6B (lanes 4

CT-1 Signaling in Adipocytes
and 5), indicating that the protein complex may be a STAT1
homodimer. Specificity of binding to the labeled oligonucleotide
(⫺221 to ⫺207) is shown in Fig. 6C. Binding of the CT-1activated protein complex was competed with an excess of the
unlabeled wild type oligonucleotide (lane 4) but not with a
mutant oligonucleotide (lane 5) nor with oligonucleotides corresponding to two other sites within the PPAR␥2 promoter that
bear resemblance to the STAT consensus sequence TTCNNNGAA (lanes 6 and 7). Since serine phosphorylation of
STATs can modulate the transcriptional activity of these proteins (27), we examined the binding of CT-1-activated STAT 1
to the ⫺221 to ⫺207 element of the PPAR␥2 promoter following
a pretreatment with U0126. The binding of STAT1 to the ⫺221
to ⫺207 oligonucleotide was moderately inhibited by the MEK
inhibitor, shown in Fig. 6D, indicating a possible role for the
Ras/MAPK pathway in regulating STAT1 binding to the
PPAR␥2 promoter. Yet, the ability of CT-1 to induce STAT 1
binding to the PPAR␥2 promoter was not dependent on active
MAPK (ERK1 and -2). To assess the importance of this STAT1
site in the CT-1-induced modulation of PPAR␥, we transiently
transfected 3T3-L1 preadipocytes with a wild type (WT in Fig.
6) PPAR␥2 promoter (⫺609 to ⫹52)/luciferase construct or with
mutant PPAR␥2 promoter (Mut) construct that had two nucleotides altered within the ⫺221 to ⫺207 region (PPAR␥2 m217/
212 (⫺609 to ⫹52)/luciferase). The results in Fig. 6E demonstrate that a 6-h treatment with CT-1 resulted in a 30%
decrease in luciferase activity of the wild type construct, indicating decreased transcription of the PPAR␥2 promoter by this
gp130 cytokine. In addition, transfection with the mutant construct revealed lower basal level of luciferase activity, indicating that this STAT1 binding site contributes to the expression
levels of this reporter/construct. Interestingly, a 6-h CT-1 treatment of preadipocytes containing the mutant construct resulted in an up-regulation of the promoter. Since the basal
levels of expression of the mutant construct are reduced, it
cannot be determined whether the mutated bases within the
⫺221 to ⫺207 region are critical for the CT-1-induced
down-regulation.
To assess the effect of chronic CT-1 treatment on 3T3-L1
adipocytes, fully differentiated adipocytes were exposed to
CT-1 over a time course of 96 h. A fresh bolus of CT-1 was
added to the cells every 24 h. As shown in Fig. 7, chronic
administration of CT-1 resulted in decreased protein levels of
FAS and IRS-1 after 72 and 96 h of treatment. The levels of
ACC, the 67-kDa form of sterol regulatory element-binding
protein-1, and Akt were unchanged. In addition, there were no
significant effects on the levels of STAT1, -3, and -5A. Interestingly, CT-1 administration resulted in a transient down-regulation of PPAR␥ protein following a 24-h CT-1 treatment. However, after 48 h, PPAR␥ levels had returned to basal levels, and
additional CT-1 treatments did not result in decreased PPAR␥
following chronic (48 –96 h) CT-1 treatment.
Since we observed a decrease in IRS-1 protein levels following a chronic CT-1 treatment of 3T3-L1 adipocytes, we examined the effects of CT-1 on insulin-stimulated glucose uptake in
these cells. As shown in Fig. 8A, a 10-min treatment with
insulin results in a nearly 6-fold increase in glucose uptake in
fully differentiated 3T3-L1 adipocytes. A 1-h pretreatment with
CT-1 did not cause a statistically significant inhibition of insulin-stimulated glucose uptake. However, we observed a decrease in insulin-stimulated glucose uptake following a 24-h
and a 96-h pretreatment with CT-1. Specifically, the 96-h CT-1
pretreatment resulted in a statistically significant 4-fold decrease in insulin-stimulated glucose uptake, as compared with
the control, that was largely due to a statistically significant
increase in basal glucose uptake, as indicated in Fig. 8B.
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FIG. 7. The effects of chronic CT-1 administration on the expression of adipocyte proteins. Whole cell extracts were prepared
from fully differentiated 3T3-L1 adipocytes following a treatment with
0.2 nM CT-1 for the times shown. One hundred g of each extract was
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis. CTL, control.

DISCUSSION

CT-1 is a newly identified member of the gp130 cytokine
family that signals via a receptor complex composed of gp130
and LIFR signal transducer proteins. Recent work from our
laboratory has shown that another member of the gp130 cytokine family, CNTF, can activate several signaling pathways
and regulate protein expression in 3T3-L1 adipocytes (20).
These effects are likely to be induced by utilizing only gp130
and LIFR as signal transducers, since the specific CNTF receptor, CNTF receptor ␣, is not expressed in fat cells in vitro (20).
Since both IL-6 and CNTF have effects on body weight regulation (28, 29), we have investigated the actions of CT-1 in vitro
and in vivo to determine whether this gp130 cytokine can
induce similar signaling effects in fat cells and regulate adipocyte gene expression.
Our results demonstrated that administration of CT-1 to
both preadipocytes and 3T3-L1 adipocytes resulted in similar
downstream responses. Interestingly, and in contrast to CNTF,
CT-1 activated STAT1 and -3, as well as ERK1 and -2 MAPKs
in both cell types, and the responses were of identical magnitudes but slightly more sustained in preadipocytes. Since the
levels of gp130 remain fairly unaffected by differentiation, and
LIFR is expressed by mature adipocytes, both preadipocytes
and mature adipocytes have a significant population of these
receptors on their cell surfaces. Therefore, both cell types are
likely to be activated by CT-1. The attenuation of the response
duration in adipocytes, as compared with preadipocytes, could
be attributed to the slight loss of LIFR expression that occurs
during adipocyte differentiation (30).
Further investigation of CT-1 actions in adipocytes revealed
that CT-1 was also capable of activating STAT5A and -5B in
vitro, in addition to STAT1 and -3. STAT5A and -5B in 3T3-L1
adipocytes were not activated by CNTF or other gp130 cytokines. Hence, their activation by CT-1 presents a rather novel
finding and may, upon further investigation, prove to be a
mechanism for the specificity of this cytokine’s action. The
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FIG. 8. The effects of CT-1 administration on insulin-stimulated glucose uptake. Serum-deprived, fully differentiated 3T3-L1
adipocytes were incubated with 0.2 nM CT-1 for the periods indicated in
the figure. Cells were then exposed to 50 nM insulin or saline control
(CTL) for 10 min. Glucose uptake was measured as described under
“Experimental Procedures.” A, values shown represent the -fold increase in glucose uptake, over basal uptake level, following the insulin
treatment (*, p ⫽ 0.023, Student’s t test). B, values shown represent the
mean ⫾ S.E. (light bars, saline control; dark bars, insulin treatment) of
triplicate determinations from two independent experiments (*, p ⫽
0.019, Student’s t test).

activation of these proteins was confirmed through their detection in the nuclear fraction from the cells following cytokine
treatment. STAT proteins translocated to the nucleus within
15 min after the treatment and were mostly absent within 2 h.
These parameters are consistent with STAT activation by other
cytokines in adipocytes (31). These data also indicate that
STATs activated by CT-1 are not only tyrosine-phosphorylated
but also translocate to the nucleus, where they can act as
transcription factors.
Interestingly, CNTF cannot activate STAT3 and ERK1 and
-2 in a dose-dependent manner in adipocytes (20). However,
adipocytes treated with a range of CT-1 doses activated STAT1,
-3, and -5 as well as ERK1 and -2 in a dose-dependent manner.
Activation of these proteins by CT-1 also occurred at much
lower doses and with higher magnitude of activation when
compared with that of CNTF. Once again, we hypothesize that
this response is due to the abundance of gp130 and LIFR in
adipocytes. Unlike CNTF, which has a limited affinity for
gp130/LIFR dimer in the absence of CNTF receptor ␣, CT-1 is
not limited by the absence of the cytokine-specific receptor
component and can bind gp130/LIFR dimer with a very high
affinity (7). LIF, a gp130 cytokine which also utilizes the gp130/
LIFR dimer to transduce its signals, is capable of activating an
identical profile of adipocyte STATs as CT-1 and also does so in
a dose-dependent manner. Thus, taking into account the results discussed so far, one can hypothesize that the availability
of receptor component proteins can significantly affect the mag-

nitude, duration, variety, specificity, and dose dependence of
gp130 cytokine response in fat cells.
Native adipocytes also express both gp130 and LIFR proteins. Hence, we investigated the in vivo effect of CT-1 administration on adipose tissue of C57B1/6J mice. We observed that
acute CT-1 was able to activate STAT1 and -3, as well as ERK1
and -2, in the epididymal fat pads of these mice, mimicking the
in vitro effects we observed in 3T3-L1 adipocytes. However, the
dose administered (0.1 nM) was not sufficient to induce the
activation of STAT5. This is consistent with the dose dependence results from the in vitro studies. Although further studies
will be necessary to determine whether CT-1 can activate
STAT5 at higher doses in vivo, it is still quite exciting to
discover that this cytokine directly affects fat tissue and may
potentially have biological roles in native adipocyte function.
Adipocyte differentiation is marked by changes in the expression of several adipocyte-specific proteins. Since CT-1 and
CNTF both activate the JAK/STAT pathway in 3T3-L1 cells,
we examined the ability of these cytokines to regulate adipogenesis. Unlike tumor necrosis factor-␣ or interferon-␥, the
presence of CT-1 or CNTF did not inhibit adipocyte differentiation. These studies suggest that the anti-obesity effects of
CNTF are not mediated by the inhibition of fat cell differentiation. Interestingly, both cytokines induced a decrease in the
expression of FAS, which we have previously observed with
chronic CNTF treatment in adipocytes (20). Since CT-1 administration to differentiating 3T3-L1 cells did not affect overall
lipid accumulation (data not shown), we cannot be certain
whether CT-1 could potentially affect lipid biosynthesis in adipocytes. However, in mature adipocytes, both gp130 cytokines
resulted in a transient decrease in PPAR␥ expression.
Although CT-1 and CNTF did not affect adipocyte differentiation, we further investigated the acute effects of these cytokines on fully differentiated 3T3-L1 adipocytes. Acute treatment of 3T3-L1 adipocytes with CNTF and CT-1 resulted in a
significant induction of SOCS-3 mRNA levels. Within 1 h, the
levels returned to basal levels in the CNTF-treated cells but
remained elevated even after 8 h in CT-1-treated adipocytes.
However, this finding was not very surprising due to the fact
that SOCS-3 mRNA levels are regulated by activated STATs
(32), and we have shown that the activation of STATs by CT-1,
especially the activation of STAT3, is temporally prolonged,
compared with activation by CNTF. Another interesting finding is that both cytokines, especially CT-1, resulted in a transient decrease of PPAR␥ mRNA levels. This is consistent with
the transient decrease in the PPAR␥ protein we observed following a 24-h CT-1 treatment (Fig. 8). Other studies have
shown that STATs activated by interferon-␥, tumor necrosis
factor-␣, IL-1, and IL-6, have the ability to down-regulate
PPAR␥ mRNA levels (33, 34). Since CT-1 is predominantly
known for its role as an activator of the JAK/STAT and MAPK
pathways, we were interested in determining which of these
pathways was involved in the induction of SOCS-3 and the
attenuation of PPAR␥ mRNA levels. When the MAPK pathway
was inhibited by using the specific MEK inhibitor U0126, we
still observed an increase in SOCS-3 mRNA and a decrease in
PPAR␥ mRNA levels following CT-1 treatment. Hence, our
studies suggest that the CT-1-induced regulation of SOCS-3
and PPAR␥ mRNA levels is independent of the MAPK (ERK1
and -2) pathway.
Since previous studies from our laboratory have demonstrated that STAT1 activated by interferon-␥ down-regulates
the expression of PPAR␥ via the ⫺221 to ⫺207 site within the
promoter (26), we investigated the ability of STAT1 activated
by CT-1 to bind this promoter element. Our findings clearly
demonstrate that CT-1 induces STAT1 binding to the PPAR␥2
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promoter element and that this binding is very specific and
may play a role in the CT-1-induced repression of PPAR␥2
promoter activity. We also observed that this regulation is
independent of the actions of MAPK. Together with our results
demonstrating that CT-1 decreases PPAR␥ mRNA levels (Fig.
7A) and results in a transient decrease in PPAR␥ protein expression (Fig. 8), we conclude that a single exposure of adipocytes to CT-1 results in a repression of PPAR␥ transcription
that is independent of MAPK activity.
In light of our results from the acute CT-1 administration, we
also examined the effects of chronic CT-1 treatment in 3T3-L1
adipocytes. Upon 96 h of treatment, CT-1 resulted in a decrease
of FAS and IRS-1 protein levels. CNTF had an identical effect
on FAS but an opposite effect on IRS-1 (20). The levels of
STATs, Akt, and sterol regulatory element-binding protein-1
remained constant throughout the treatment, unlike that of
PPAR␥. CT-1 first induced a transient decrease in the protein
levels, consistent with the decrease in mRNA levels we observed in the acute treatment. However, PPAR␥ protein expression was then transiently increased before returning to the
basal level. The ability of CT-1 to regulate PPAR␥ may prove to
be interesting in its relation to effecting adipocytes, particularly since CT-1 did not inhibit PPAR␥ expression in differentiating cells. More importantly, the down-regulation of IRS-1
expression by CT-1 could be a possible marker of impaired
insulin sensitivity in CT-1-treated adipocytes. Our observation
that chronic (96 h) CT-1 treatment of fully differentiated
3T3-L1 adipocytes results in a statistically significant decrease
in insulin-stimulated glucose uptake (Fig. 8A) supports our
hypothesis that CT-1 may be a mediator of impaired insulin
sensitivity. However, further work should be done to address
these results, particularly since our findings (Fig. 8B) indicate
that a 96-h CT-1 treatment leads to a statistically significant
increase in basal glucose uptake, rather than a notable decrease in insulin-stimulated uptake. We hypothesize that the
increase in basal uptake may be due to increased GLUT1
expression. Currently, there are no reports of increased circulating levels of CT-1 in conditions of insulin resistance, yet we
hypothesize that the modulation of IRS-1 by CT-1 may serve as
a model of insulin resistance to study the effect of elevated
circulating levels of CT-1 in the serum of patients with ischemic heart disease and valvular heart disease (21). Clinical
aspects of these diseases are tightly linked to obesity/type 2
diabetes (22, 23), whereas the principal cause of diabetes mortality is cardiovascular disease (35). Therefore, CT-1 may act as
a link between obesity-related complications and cardiovascular disease.
In summary, we have observed that CT-1 acts as a potent
activator of both JAK/STAT and MAPK pathways in both preadipocytes and 3T3-L1 adipocytes as well as in rodent fat pads in
vivo. Unlike CNTF, CT-1 activation of these pathways is more
robust, dose-dependent, and sustained. This is also the first
report of STAT5 activation by a gp130 cytokine in 3T3-L1
adipocytes. Although neither CNTF nor CT-1 had any significant effects on adipocyte differentiation, both cytokines induced transient changes in SOCS-3 and PPAR␥ mRNA and
protein levels in adipocytes. Since other gp130 cytokines, such
as leptin and CNTF, have been implied as potential mediators
of various aspects of obesity/type 2 diabetes, it would be inter-
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esting to further investigate the actions of CT-1 in this area.
However, the strongest focus should be placed on measuring
the circulating levels of CT-1 in obesity/type 2 diabetes patients
and the effects of this cytokine on insulin-sensitive tissues.
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